These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 7752292)

  • 21. Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial.
    Robertson JR; Raab GM; Bruce M; McKenzie JS; Storkey HR; Salter A
    Addiction; 2006 Dec; 101(12):1752-9. PubMed ID: 17156174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A primary care/multidisciplinary harm reduction clinic including opiate bridging.
    Ross D; Lo F; McKim R; Allan GM
    Subst Use Misuse; 2008; 43(11):1628-39. PubMed ID: 18752164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical mismanagement in public methadone programs.
    Blansfield HN
    Conn Med; 1994 Mar; 58(3):161-4. PubMed ID: 8039380
    [No Abstract]   [Full Text] [Related]  

  • 24. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
    Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA
    Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment outcomes for methadone clients receiving lump-sum payments at initiation of disability benefits.
    Herbst MD; Batki SL; Manfredi LB; Jones T
    Psychiatr Serv; 1996 Feb; 47(2):119-20, 142. PubMed ID: 8825244
    [No Abstract]   [Full Text] [Related]  

  • 26. Profiles of self-reported HIV-risk behaviors among injection drug users in methadone maintenance treatment, detoxification, and needle exchange programs.
    Mark HD; Nanda J; Davis-Vogel A; Navaline H; Scotti R; Wickrema R; Metzger D; Sochalski J
    Public Health Nurs; 2006; 23(1):11-9. PubMed ID: 16460416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Methadone substitution treatment. Results of an evaluation of 3 years implementation in an Austrian province].
    Rittmannsberger H; Ruschak M; Silberbauer C
    Nervenarzt; 1994 May; 65(5):338-44. PubMed ID: 8052337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment.
    Stenbacka M; Beck O; Leifman A; Romelsjö A; Helander A
    Drug Alcohol Rev; 2007 Jan; 26(1):55-63. PubMed ID: 17364837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescription opioid abuse among enrollees into methadone maintenance treatment.
    Rosenblum A; Parrino M; Schnoll SH; Fong C; Maxwell C; Cleland CM; Magura S; Haddox JD
    Drug Alcohol Depend; 2007 Sep; 90(1):64-71. PubMed ID: 17386981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Financing and cost of standard and enhanced methadone treatment.
    Bradley CJ; French MT; Rachal JV
    J Subst Abuse Treat; 1994; 11(5):433-42. PubMed ID: 7869464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial.
    Strathdee SA; Ricketts EP; Huettner S; Cornelius L; Bishai D; Havens JR; Beilenson P; Rapp C; Lloyd JJ; Latkin CA
    Drug Alcohol Depend; 2006 Jul; 83(3):225-32. PubMed ID: 16364566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retention in publicly funded methadone maintenance treatment in two Western States.
    Deck D; Carlson MJ
    J Behav Health Serv Res; 2005; 32(1):43-60. PubMed ID: 15632797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs.
    Des Jarlais DC; Paone D; Friedman SR; Peyser N; Newman RG
    Am J Public Health; 1995 Nov; 85(11):1577-84. PubMed ID: 7485676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Program changes and retention on methadone.
    Maddux JF; Vogtsberger KN; Desmond DP; Esquivel M
    J Subst Abuse Treat; 1993; 10(6):585-8. PubMed ID: 8308944
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of offering free treatment to street-recruited opioid injectors.
    Kwiatkowski CF; Booth RE; Lloyd LV
    Addiction; 2000 May; 95(5):697-704. PubMed ID: 10885044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals.
    Hall G; Neighbors CJ; Iheoma J; Dauber S; Adams M; Culleton R; Muench F; Borys S; McDonald R; Morgenstern J
    J Subst Abuse Treat; 2014 Apr; 46(4):511-5. PubMed ID: 24468235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subsidising patient dispensing fees: the cost of injecting equity into the opioid pharmacotherapy maintenance system.
    Chalmers J; Ritter A
    Drug Alcohol Rev; 2012 Nov; 31(7):911-7. PubMed ID: 22624529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Another wall that crumbled--methadone maintenance treatment in Germany.
    Newman RG
    Am J Drug Alcohol Abuse; 1995 Feb; 21(1):27-35. PubMed ID: 7762542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis of HIV risk-reduction interventions within drug abuse treatment programs.
    Prendergast ML; Urada D; Podus D
    J Consult Clin Psychol; 2001 Jun; 69(3):389-405. PubMed ID: 11495169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of streamlined admissions to methadone treatment: a simplified time-series analysis.
    Dennis ML; Ingram PW; Burks ME; Rachal JV
    J Psychoactive Drugs; 1994; 26(2):207-16. PubMed ID: 7931865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.